Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Open and sustainable AI: challenges, opportunities and the road ahead in the life sciences.

Nature methods·2026

Same author

A fixed mutation in the respiratory complex I impairs mitochondrial bioenergetics in the endangered Apennine brown bear.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Toward a framework for risk mitigation of potential misuse of artificial intelligence in biomedical research.

Nature machine intelligence·2025

Same author

Federated learning for the pathogenicity annotation of genetic variants in multi-site clinical settings.

Bioinformatics (Oxford, England)·2025

Same author

Paying attention to attention: High attention sites as indicators of protein family and function in language models.

PLoS computational biology·2025

Same author

Protein functional site annotation using local structure embeddings.

Proceedings of the National Academy of Sciences of the United States of America·2025

Search research articles

Related Experiment Video

Updated: May 22, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Bioinformatics and variability in drug response: a protein structural perspective.

Jennifer L Lahti¹, Grace W Tang, Emidio Capriotti

¹Department of Bioengineering, Stanford University, Stanford, CA, USA.

Journal of the Royal Society, Interface

|May 4, 2012

Summary

Understanding genetic variations in drug targets is key to personalized medicine. This review explores how protein structure changes due to genetic differences impact drug effectiveness and safety.

More Related Videos

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

Published on: January 26, 2024

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Related Experiment Videos

Last Updated: May 22, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

Published on: January 26, 2024

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Area of Science:

Pharmacology
Structural Biology
Genetics

Background:

Marketed drugs often show variable efficacy and safety profiles in clinical practice compared to trial results.
A significant patient subpopulation may not respond to therapies or experience severe adverse effects, highlighting the need for personalized medicine.

Purpose of the Study:

To elucidate the molecular mechanisms behind differential drug responses in diverse patient populations.
To bridge advances in structural genomics and pharmacogenetics for a deeper understanding of drug-target interactions.

Main Methods:

Reviewing structural characteristics of drug target proteins and common drug interaction mechanisms.
Analyzing the impact of genetic coding mutations on protein structure and subsequent drug response.
Highlighting computational tools for analyzing protein structures and drug interactions.

Main Results:

Genetic variations can alter protein structures, influencing drug binding and therapeutic outcomes.
Structural genomics and pharmacogenetics provide a framework for understanding patient-specific drug responses.
Tools exist to analyze these structural variations and their effect on drug efficacy.

Conclusions:

A paradigm shift towards personalized medicine is necessary due to variable drug responses.
Understanding genotype-phenotype correlations at the molecular level is crucial for optimizing drug therapy.
Structural analysis of drug targets offers a path to predict and manage altered drug responses.